Safety and Efficacy of SDX-101 (R-Etodolac) in Patients With Relapsed or Refractory Multiple Myeloma (MM)

This study has been terminated.

Study NCT00293111 Information provided by Cephalon

First Received: February 16, 2006 Last Updated: April 19, 2006 History of Changes

No Study Results Posted for this Study

Study Status:	This study has been terminated.
Estimated Study Completion Date:	No date given
Estimated Primary Completion Date:	No date given